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ABSTRACT
THE REGULATION AND MECHANISMS OF EGFR-MEDIATED APOPTOSIS
IN MDA-MB-468 CELLS
Nicole Marion Jackson
July 21, 2015
Background: The Epidermal Growth Factor Receptor (EGFR) is a 170kilodalton transmembrane protein that belongs to the ErbB family of receptor
tyrosine kinases. Upon ligand-mediated activation, the EGFR responsible for cell
growth, proliferation, and tissue homeostasis in epithelial cells; however, the
EGFR is overexpressed in many human malignancies including MDA-MB-468
cells, a metastatic breast epithelial cell line. Previous studies have indicated that
within the MDA-MB-468 cell line, receptors at the cell surface promote cell
growth when activated with Epidermal Growth Factor (EGF) ligand. Activated
receptors that are internalized to the endosomes however induce apoptosis. This
contrasting response at different cellular locations is defined as spatial regulation.
The overarching research goal of this thesis is to better understand the spatial
regulation within these cells, and identify the effector proteins responsible for the
difference in signals emanated at the cell membrane versus intracellularly. The
goals of this thesis were to first determine whether other EGFR ligands,
Betacellulin (BTC) and Transforming Growth Factor-alpha (TGFA), are able to
induce apoptosis in the MDA-MB-468 cell line. The second goal was to identify
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effectors downstream of EGFR activation that could have potential implications in
EGFR-mediated apoptosis. Methods: An MTT assay was conducted in order to
evaluate the viability of the MDA-MB-468 cells after treatment and activation with
3 EGFR ligands: EGF, BTC, or TGFA. EGF activity was measured as a function
of receptor phosphorylation. Western blot analysis was conducted after MDAMB-468 cell exposure to increasing concentrations of the three ligands. This was
done in order to identify any variances or similarities in phosphorylation patterns
amongst the three ligands. Lastly, cell morphology was observed after the cells
were exposed to 16 nM concentrations of each ligand for 24 hours. A different
approach to assessing EGFR spatial regulation was then employed. MDA-MB468 cells were subjected to time course and dose response experiments, prior to
the ultimate assessment of various different effectors. Results: All ligands
induced dose dependent decreases in cell viability. All three ligands signaled
through the EGFR, as measured by receptor phosphorylation, with similar
phosphorylation patterns. Western blot analyses indicate a dose dependent
increase in EGFR phosphorylation in response to all ligands. MDA-MB-468 cells
were round in morphology at 24-hour time points with exposure to high
concentrations of all ligands. An effector screening was conducted, which
resulted in the discovery of upregulated STAT3 activity, preferentially with high
EGF concentrations. This suggests the potential for STAT3 to mediate apoptosis,
and be spatially regulated in MDA-MB0468 cells. After confirming the
upregulation of STAT3 in an EGFR dependent manner, commercially available
inhibitors of STAT3 were employed; however the inhibitors exhibited non-specific
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effects, in vitro. Conclusions: These data suggest that EGFR signaling in MDAMB-468 cells is not ligand specific, and that activation and internalization of the
receptor in this cell line with any endogenous ligand will result in cell death. The
results indicate a potential role of STAT3 in EGFR-induced apoptosis. Future
experiments will entail employing siRNA targeting STAT3 in order to determine
the role of STAT3 in EGFR-induced apoptosis.
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BACKGROUND AND INTRODUCTION

The epidermal growth factor receptor (EGFR) is a cell surface receptor
that is expressed in almost every tissue of the body and plays critical roles in
development and tissue homeostasis. Further, many cancers are characterized
by hyper-activated EGFR signaling, either due to overexpression of the receptor
or somatic activating mutations of the receptor. These perturbations in EGFR
expression and/or activation are associated with poor patient prognosis. Over the
last 15-20 years, there has been a concerted effort to develop cancer
therapeutics that specifically target the aberrant EGFRs, with the goal of
inhibiting the progression of those cancers. Understanding the basic cell biology
of the EGFR helps to understand its implications, and define its typical role in
normal cell biology.
In order to better understand the function of the EGFR, it is best to start
with the discovery of one of the principal ligands that initiates its activity. Dr.
Stanely Cohen isolated and discovered its endogenous ligand, Epidermal Growth
Factor (EGF) from murine submaxillary glands in the early 1960’s. Frozen
submaxillary glands were obtained from mice and homogenized in acetic acid,
prior to being frozen in a dry ice-alcohol bath. The material was then thawed and
subjected to a series of ultra-centrifugations at 100,000 x g, and acetic acid
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washes. The newly formed pellet was then subjected to size exclusion, and ion
exchange chromatography for purification [1]. Amino acid analysis of the purified
product revealed that EGF is a 53 amino acid residue polypeptide, containing
three internal disulfide bonds, as depicted in Figure 1.
Dr. Cohen observed that injecting the purified, crude, submaxillary gland
preparations into newborn mice stimulated growth of embryonic neurons and
induced precocious eyelid opening. Having identified a growth factor that was
able to initiate some very specific physiological responses, the next goal was to
identify the receptor. In 1978, he and Dr. Graham Carpenter were able to identify
the presence of the 170 kilodalton EGFR specific for EGF ligand through the use
of radiolabeled (125 I-labeled) EGF ligand in A-431 cells, a human epidermoid
carcinoma cell line. They reported increased 32P incorporation in the A-431 cells
in response to EGF ligand stimulation, suggesting that phosphorylation of EGFR
components might be critical for its function [2]. In 1982, Dr. Cohen proceeded to
then successfully isolate and purify the EGFR from A-431 cells, and from normal
mouse liver cells by means of affinity chromatography. Purification of the
receptor aided in the confirmation that the EGFR was able to bind 125 I-labeled
EGF, and that the receptor possessed ligand stimulated, intrinsic kinase activity,
which was responsible for auto-phosphorylation of tyrosine residues, upon
binding of EGF. This particular study also confirmed that the receptor in normal
liver cells had biochemical similarities to receptors found in the carcinoma cell
line [3]. The contributions of Dr. Cohen and Dr. Carpenter have allowed for
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Figure 1. The amino acid sequence of EGF ligand, isolated and purified from
murine submaxillary glands. (from Journal of Biological Chemistry (1973) 248,
7669-7672)
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subsequent studies to unveil further information about the receptor, including its
physiology, function, and regulation.
Another huge leap in our understanding of the molecular mechanism of
EGFR-mediated signaling came in 1984 when Ullrich and colleagues used the
newly identified tools of molecular biology to clone the human EGFR. From this
report, a model (which has been modified numerous times over the years) was
generated that described the functional domains of the EGFR.
The EGFR is comprised of three major domains: 1) an extracellular, ligand
binding domain with cysteine rich regions, 2) a cytosolic, intrinsic kinase domain,
and 3) a cytosolic domain containing tyrosine residues [4]. Studies by Lax et al.
devised a method utilizing 125 I-labeled EGF to label the EGFR for subsequent
isolation, and cleavage through use of Cyanogen Bromide (CNBr). Site-specific
antibodies were then used to identify certain residues (293 and 543) that are
critical for the function of the receptor. On the basis of amino acid sequence
conservation, it was then determined that the extracellular domain was
comprised of 600 amino acids, and could be divided into 4 sub-domains [5].
Domains I and III are ligand binding regions, with 37% homology that physically
bind the ligand. Domains II and IV are rich in cysteine, and have 17% amino acid
homology that interfaces with other receptors for dimerization [6, 7].
The model of how these domains come together is based on
crystallographic analysis that was done by the Lemmon laboratory. In the
unliganded state, the cysteine-rich domains of a monomeric receptor bind to one
another through an intramolecular interaction. Upon the introduction of ligand,
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the receptor undergoes a conformational change such that both ligand binding
domains bind the ligand and disrupt the interaction between the two cysteine rich
domains. The exposure of cysteine rich domain I then can interact with the
corresponding domain with another EGFR to form a dimer. Ligand binding also
brings about a conformational change that activates the intrinsic kinase domain,
which then leads to autotransphosphorylation of the cytosolic tyrosine residues
[8]. The kinase domain of each receptor moiety will phosphorylate tyrosine
residues on its adjacent dimer partner by a conformational change in the receptor
that places the tyrosine substrate in access to the kinase domain. These
phosphotyrosines then serve as docking sites for various cytoplasmic enzymes,
known as effector molecules. By docking to the phosphotyrosines, these
effectors become activated and modulate various cellular processes that
contribute to the overall cell biology [9]. For example, activation of the EGFR by
EGF leads to activation of the Janus Kinase (JAK) tyrosine kinase in the cytosol.
The JAK protein then proceeds to phosphorylate and activate the signal
transducers and activators of transcription (STAT) proteins [10]. This JAK/STAT
signaling cascade is a pathway implicated in cell survival responses [11].
Activation of alternative downstream signaling cascades by the EGFR induces
known responses for cellular differentiation, proliferation, migration, and
protection from apoptosis [12].
Although the EGFR is expressed at the cell surface of many normal cells,
and is critical for animal development and cellular homeostasis, it is often
mutated and/or hyper-expressed in a number of human malignancies [13]. In a
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study conducted by Real et al., mouse monoclonal antibodies specific for the
EGFR were used to assess the distribution of the receptor in various human cell
and tissue types. These studies have confirmed EGFR expression in normal
stomach, bladder, colon, esophageal, and lung tissue; however, no expression
was determined in normal brain tissue or skeletal muscle [14]. In regard to
malignant cells and tissue, the EGFR has shown to be hyper-expressed in colon,
kidney, lung and sarcoma cancers; however, it is non-prevalent in primary
melanoma [14] and gliosarcoma malignancies [15].
In the analysis of large populations of cancers with EGFR mutations, one
of the most common mutations entails a deletion of exons 2-7 of the EGFR gene
that removes virtually the entire extracellular domain of the receptor. In the
absence of a ligand binding domain or cysteine rich domains that have
intramolecular binding that prevents dimerization, this receptor is free to
associate with other mutant receptors and is constitutively active. This mutant
receptor is referred to as EGFRvIII, and is substantially expressed in patients
with glioblastoma malignancies [16, 17]. Mutated tyrosine residues of the EGFR
at the cytosol have also been shown to induce aberrant signaling as well as drug
resistance in cancers characterized by hyper-expression of the EGFR [18, 19]. In
addition to the EGFR itself, studies have shown that alterations in EGFR ligand
expression can hinder certain tissue physiology. Luetteke et al. bred knockout
mice that lacked endogenous expression of various, endogenous EGFR ligands.
Pups born to these knockout mice were runted, and showed stunted growth and
survival. These data provide confirmation of a requirement for EGFR ligands to
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initiate receptor signaling in order for proper development of the mouse
mammary gland [20]. Overall, it can be inferred that regulation of tyrosine
phosphorylation as well as endogenous EGFR ligands are both critical for proper
signaling and modulation of cellular effects of the activated receptor.
Numerous cellular processes play a role in controlling EGFR activity. Chief
among these is ligand-mediated endocytosis. Co-incident with ligand binding to
the EGFR and activation of the intrinsic kinase domain, the ligand:receptor
complex is internalized into the cell in either a clathrin-mediated, or clathrinindependent manner. Clathrin-coated vesicles were first identified in osteocytes
[21], and then later in neurons [22]. In 1975, Barbara Pearse biochemically
characterized these clathrin-coated vesicles as transport vesicles upon isolating
and purifying them from pig brains prior and analyzing their physical properties
via electron microscopy. She described these vesicles as intracellular vesicles
with unique “coats” on their cytoplasmic surfaces [23]. Her discovery serves as
the foundation of biochemical studies entailing clathrin-mediated endocytosis and
membrane trafficking in general.
Sigismund et al. stimulated receptor activation with EGF for 2 minutes in
HeLa cells prior to immunostaining and subjecting the fixed cells to
immunoelectron microscopy. Immunoelectron microscopy allowed for viewing
and imaging of the immunostained cells in their various compartments during
EGFR mediated endocytosis [24]. These studies, as well as subsequent studies,
revealed that Clathrin-mediated EGFR endocytosis is observed at all ligand
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concentrations, where as with higher concentrations of ligand, (10-100 ng/mL)
the receptor undergoes Clathrin-independent endocytosis via caveolae [25, 26].
Once internalized within the cell, the EGFR is subjected to the endocytic
pathway, a pathway responsible for sorting and determining the ultimate fate of
the internalized ligand:receptor complex. An intermediate vesicle containing the
ligand:receptor complex fuses with an early endosome. The mildly acidic
environment of the early endosome (pH 6) allows for certain EGFR ligands (EGF
and transforming growth factor–alpha (TGFA)) to dissociate from the EGFR,
should the ultimate fate of the receptor be recycling back to the plasma
membrane [27]. From here, the unbound-receptor will recycle back to the cell
membrane via recycling endosomes for additional ligand binding and signaling.
These recycling endosomes, slightly acidic at pH 6.4, are generally located within
the cell, and are centered around the microtubule-organizing center [28]. These
recycling endosomes exhibit tubular-vesicular morphology, which suggests
dynamic trafficking activity and supports their involvement with the underlying
connection of endocytosis with exocytosis [29, 30]. Should the ligand:receptor
complex remain inside of the early endosome, however, the early endosome will
mature into a late endosome with the complex intact. The late endosome then
fuses with the lysosome just prior to the ultimate degradation of the
ligand:receptor complex [31]. This endocytic pathway is essential for regulating
the activity of the EGFR, both temporally and spatially. Temporally, meaning that
the time it takes the receptor to transverse the entire endocytic pathway will
ultimately dictate the duration of its signaling. Spatially, in regard to the fact that
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at different subcellular locations, the receptor will interact with different effector
proteins, activating different signaling cascades [32].
Due to hyper-expression of the EGFR in a number of human
malignancies, including kidney, breast, pancreatic, and cervical cancers [33], the
correlation between signaling by the EGFR and the endocytic pathway has
important implications in both receptor tyrosine kinase and cancer biology [32].
One approach utilized to assess this correlation involves studying EGFR
signaling and endocytosis upon activation with different ligands. Currently, there
are seven identified growth factor proteins that are able to bind to and activate
the EGFR: these include EGF, amphiregulin (AREG), betacellulin (BTC), epigen
(EPGN), epiregulin (EREG), heparin-binding EGF-like growth factor (HBEGF),
and TGFA [34]. Although each of these ligands stimulates EGFR activation and
internalization, they yield diverse effects on endocytic sorting [35]. This
information can be used advantageously to assess the differential effects and
regulatory mechanisms different ligands have on EGFR signaling. One of the
critical components of this thesis entails determining if EGFR ligands have
differential effects on EGFR-mediated apoptosis.
EGF is a 53 amino acid, 6.4 kilodalton (kDa) protein that has been shown
to be involved in regulation of cellular proliferation in mammals [36, 37]. Similarly
to EGF, TGFA ligand contains 50 amino acids and has a molecular weight of
approximately 6 kDa. Both EGF and TGFA bind the EGFR; however, TGFA
binds with 10-30 fold less affinity to the receptor in rat hepatocytes in comparison
to EGF. Thoresen et al. isolated hepatocytes from Wistar rats prior to stimulating
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the cells with increasing concentrations of 125 I-EGF and 125 I-TGFA. Surface
binding curves after 24-hour ligand exposure exhibit a binding affinity of 11.9 nM
for TGFA, and 0.42 nM for EGF. The data within this study suggest that the two
ligands compete for a single population of binding sites in rat hepatocytes,
although EGF has a significantly higher binding affinity for the EGFR than TGFA
[38]. It is important to note that TGFA is synthesized and most prevalent in
cancer cells, and cells transformed by oncogenes and retroviruses [39]. BTC, a
slightly larger ligand (9 kDa) comprised of 80 amino acids, was originally isolated
from mouse insulinoma cells, and is able to activate EGFR and ErbB4 [40].
Studies utilizing 125 I-BTC in

fibroblasts confirm a binding affinity of

0.5 nM for the EGFR, and suggest that the preferred receptor for BTC is the
EGFR [41].
All three of these ligands are able to bind to the EGFR, and stimulate
kinase activity; however, they differ in regard to their binding affinities to the
EGFR, and their ultimate fates upon endocytosis and endocytic trafficking. In
order to compare ligand internalization upon EGFR stimulation, Roepstorff et al.
used an approach of pre-binding various EGFR ligands on ice to view the
synchronized wave of receptor internalization. After determining optimal
incubation time using 125 I-EGF, HEp2 cells were incubated with increasing ligand
concentrations for 100 minutes. The amount of total cell surface receptors was
then determined by means of FACS analysis. These data show that EGF and
BTC ligands both target the EGFR for lysosomal degradation. In contrast, TGFA
almost always leads to recycling of the EGFR to the cell membrane within 90
!

10!

minutes of ligand exposure [35]. EGF and BTC can both withstand the acidic
conditions of the endosomes, dissociating at around pH 5. In contrast, TGFA
rapidly dissociates from the receptor at pH 7, and is unable to withstand the
acidic environment of the early endosome. This therefore causes the ligand-free
receptor to recycle back to the cell membrane [35, 42]. The fate of the EGFR,
whether it is for degradation or recycling, is critical for its duration of signaling,
which will vary based on different ligands bound to the receptor. This has
ultimate implications in the initiation different signaling cascades.
In summary, the EGFR is a transmembrane receptor tyrosine kinase with
critical implications in normal cell growth, proliferation, wound healing, and tissue
homeostasis. It is regulated in both a spatial and a temporal manner. Trafficking
of the receptor can vary depending on the ligand it is bound to. The EGFR is
however hyperexpressed in mammalian cancer [33]. There is more known about
EGFR cell biology in non-malignant tissue, more so than in cancer cells.
Research has shown that pharmaceutically available EGFR inhibitors provided to
cancer patients triggers autophagy, a degradative process that actually helps
cancer cells withstand nutrient-poor conditions [43]. The primary focus of this
thesis is to better understand the function and role of the EGFR in cell growth
and apoptosis in cancer. Doing so will require determining if different ligands
have varying effects on cell viability and apoptosis. It is also of interest to identify
specific proteins with direct implications in EGFR-induced apoptosis. This will
help to develop better, more efficacious therapy for cancers that hyperexpress
the receptor.
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CELL DEATH AND APOPTOSIS

The EGFR is typically associated with cell growth, development and tissue
homeostasis; however, it has been also known to mediate cell death in cancers
that hyperexpress EGFRs [44-46]. Using a cell line that undergoes EGFRmediated apoptosis uniquely allows for the enlightenment of the biochemical
regulation of signaling by using a sensitive, tractable and irreversible readout.
These findings can be used to better understand other signaling pathways and
biological responses to cell growth, and its counterpart, programmed cell death.
The term apoptosis entails the process of programmed cellular death in
both single-cellular and multicellular organisms. Programmed cell death refers to
the time and position of cell death during development of a given organism. It has
many functions during the development process, including adjusting and deleting
cell numbers [47]. Both apoptosis and programmed cell death are normal
processes in growth, development and aging as a homeostatic mechanism for
proper maintenance of cell populations in tissues [48]. John Kerr first used the
term apoptosis in 1972, in order to describe a morphologically distinct form of cell
death. Through the use of light and electron microscopy, morphological events
that occur during apoptosis have been identified [49]. The process of apoptosis
entails structural changes that take place in two distinct stages: During stage
one, the cell rounds in shape, shrinks, and breaks into well-preserved fragments.
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Its nuclear and cytoplasmic compartments condense, causing the cellular
organelles to become more tightly packed as well as fragmented [48, 50].
Pyknosis, or chromatin condensation, is a key characteristic component of
apoptosis [48]. During the second stage, the apoptotic body, a small sealed
membrane that is released by cells undergoing programmed cell death [51], is
taken up by other cells just prior to being degraded and broken down within the
lysosome [50]. This helps to remove any superfluous material, and provide
nutrients that were once in the apoptotic cell to the cell that is viable [52]. The
apoptotic process is a critical component in normal human embryonic
development, and tissue homeostasis in all living organisms [48, 53]. However,
cancer cells often have the ability to avoid apoptosis, and continue to proliferate
[54]. This dysregulation of apoptosis is associated with many malignancies,
including breast, ovarian and colon cancers [55, 56]. Consequently, this can lead
to cellular accumulation within a given organism, creating a permissive
environment for genetic instability and oncogene activation. These events are
known to disrupt cell turnover and function, as well as damage and kill healthy,
viable cells [57].
Alternatively to apoptosis, cell death can also occur in a necrotic manner.
Necrosis is considered to be a degradative, toxic process that consequently
induces cell swelling [58, 59], opposite of apoptosis [58]. Necrosis is an
uncontrolled process and requires no energy input. It typically affects a large
population of cells, and causes inflammation, in vivo. Conversely, apoptosis is a
controlled and energy-dependent process that does not induce inflammation, and
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can occur in individual cells as well as large clusters of cells [48]. The manner of
cell death by either necrosis or apoptosis depends on the nature of the tissue
type, its developmental stage, and the cell death signal itself [60].
There are several biochemical modifications of apoptotic cells, which can be
used to help differentiate and identify them. Such modifications include DNA
breakdown, phagocytic recognition, and protein cleavage and cross-linking [61].
The caspase proteins are a family of aspartic acid-specific proteases that have
proteolytic activity and are major effectors of apoptosis [48, 62]. They are
normally synthesized as inactive precursors, or pro-enzymes, and only become
activated upon the induction of apoptosis. The pro-enzymatic form gets cleaved
and activated by other caspases, initiating a signaling cascade as well as
apoptosis induction [62]. Currently, there are 14 caspases that have been
identified [63]. These are categorized into three subgroups based on their
function within the signaling cascade. Initiator capsases (caspases 2, 8, 9, and
10) begin the cascade by activating and cleaving the executioner caspases
(caspases 3, 6, and 7) at aspartic acid residues. Once executioner caspases are
activated, they cleave and activate other cellular substrates, such as poly (ADPribose) polymerase (PARP), ultimately starting the apoptotic process [48, 64].
The third subgroup of caspase proteins includes caspases 1, 4 and 5, which
have more active roles in cytokine maturation [65].
Mechanistically, apoptosis is quite complex, involving two main pathways:
the extrinsic and intrinsic pathways (Figure 2). The extrinsic signaling pathway
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Figure 2. Schematic representation of apoptotic events. (Adapted from
Elmore et al., Toxicol Pathol., 2007)
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entails initiating apoptosis via transmembrane receptor-mediated interactions.
These receptors are known as “death receptors”, and are members of the tumor
necrosis factor (TNF) receptor family [66]. Members of this family have a “death
domain”, which is a cytoplasmic domain comprised of 80 amino acids.
The death domain of TNF receptors is primarily responsible for relaying
signals for cell death from the cell membrane to the intracellular signaling
pathways [48, 67]. Upon ligand binding, adapter proteins are recruited to the
death receptors at corresponding death domains. For instance, Fas ligand, a
ligand with a known biological function of inducing apoptosis [68], binds to the
Fas receptor, a member of the TNF receptor family. This ligand-receptor
interaction promotes the intracellular recruitment of the FADD adapter protein
[69]. FADD then associates with procaspase-8, forming a death-inducing
signaling complex (DISC). This then results in the auto-catalytic activation of
caspase-8 from procaspase-8 [70]. The activated caspase-8 then activates
executioner caspases, which leads to the induction of apoptosis. Defects in Fas
ligand and Fas receptor are causes of various autoimmune diseases. It has been
shown that upon knocking out the fas gene by homologous recombination,
generalized lymphoproliferative disease (gld) can be completely recapitulated in
mouse models [71]. Similarly, gld can be completely cured by simply expressing
the normal fas gene in the same knockout mice [72]. These studies exhibit how
critical Fas-induced apoptosis is to the regulation and cellular homeostasis of
immunocompromised organisms.
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The intrinsic signaling pathway of apoptosis initiates apoptosis in a nonreceptor mediated manner. This pathway entails mitochondrial- initiated events,
involving certain stimuli that send intracellular signals to act on specific targets
within the cell. These intercellular signals can be positive or negative signals.
Negative signals often lead to withdrawal of certain growth factors, which fails to
suppress death processes and essentially triggers apoptosis. On the other hand,
positive signals include those for free radicals, toxins, and viral infections [48].
Apoptotic signals originating from the cell surface lead to the release of
cytochrome c from the mitochondria into the cytosol, where it ultimately binds to
the Apoptotic Protease Activation Factor-1 (Apaf-1). The binding of cytochrome c
to Apaf-1 initiates apoptosome formation, which catalyzes the activation of
caspase 9 [48, 73]. Identical to the extrinsic pathway of apoptosis, activation of
caspase 3 then leads to the downstream induction of apoptosis.
Although the EGFR is typically associated with cell growth and
proliferation, forms of cancer that hyper-express the receptor often undergo
EGFR-mediated apoptosis. MDA-MB-468 cells are a metastatic breast epithelial
cell line, derived from the M.D. Anderson Cancer Center in Houston, Texas [74].
In this cell line, the EGFR is hyper-expressed, with approximately 1.3 X 106
receptors per cell [75]. Initial studies with this cell line revealed that lower than
physiological levels of EGF ligand (1 ng/mL) enhance cell growth; however,
ligand concentrations that exceed 10 ng/mL induce dose dependent decreases in
cell viability [44] . Studies within the Ceresa laboratory utilizing MDA-MB-468
cells have shown that when activated and retained at the cell membrane, the

!

17!

EGFR elicits signals for cell growth; however, once internalized within the
endosomes, the receptor elicits signals for apoptosis. Polystyrene beads of 0.9micrometer size covalently conjugated to EGF ligand were used for this
determination. The polystyrene bead itself is too large for clathrin-mediated
internalization. The conjugated EGF is able to activate the receptor while the
bead retains the activated receptor to the cell membrane. Cells treated with EGF
beads did not activate Caspase 3, where as cells treated with soluble EGF did
activate Caspase 3.
Immunoblot analyses from the Ceresa laboratory have disclosed that
there is a defect in endocytic trafficking within this cell line [76]. Through use of
Percoll gradient and indirect immunofluorescence assays, Rush et al. have
shown that instead of traversing the entire endocytic pathway to the lysosome for
degradation, the EGFR accumulates on the limiting membrane of the early
endosome in MDA-MB-468 cells. In the same study, HeLa cells, which express
physiological levels of EGFR and do not undergo EGF-induced apoptosis, were
treated with Monensin in order to block the acidification of the early endosome.
This essentially stopped trafficking of the EGFR beyond the endosome, causing
EGFRs to accumulate in the early endosome, mimicking the same defect found
in the MDA-MB-468 cell line. Treatment with Monensin and EGF ligand in HeLa
cells caused the cells to undergo EGFR-mediated apoptosis [77].

In summary, apoptosis and programmed cellular death are normal
processes within the lifespan of the cell. There are key physiological and
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morphological features that distinguish apoptotic cells from necrotic and viable
cells. The EGFR is implicated in apoptosis in cell lines that hyperexpress it. Data
from the Ceresa laboratory indicate that in addition to undergoing EGFRmediated apoptosis, this apoptotic process is spatially regulated within MDA-MB468 cells. Progression within this project involves determining all of the
necessary protein components implicated in EGFR-mediated apoptosis.
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REVIEW OF PKG AND STAT3

There are two major goals of this project: the first being to determine
whether or not various EGFR ligands induce differential outcomes on viability
and apoptosis. The second goal was to identify proteins suspected of having
direct implications in the EGFR-induced apoptotic process in the MDA-MB-468
cell line. As previously mentioned, it has been shown that low ( 10 ng/mL)
concentrations of EGF ligand enhance cell growth within this cell line. Ligand
concentrations that exceed 10 ng/mL induce cell death [44].
An EGFR-effector screening was conducted by means of western blot
analysis, upon exposing MDA-MB-468 cells to low (1 ng/mL) and high (100
ng/mL) EGF for various time points within a 2-hour period. Additionally, dose
response experiments were conducted with increasing concentrations of EGF
ligand for effector determinations as well. Protein effectors downstream of EGFR
activation were expected to be upregulated with low ligand treatment if they had
implications in cell growth. Conversely, effectors that were upregulated with high
ligand treatment were assumed to have implications with cell death. After
completing the effector screening, only two protein candidates were identified
with potential correlation to upregulated EGFR with high ligand treatments: PKG
and STAT3. This chapter serves to provide background of both effector
candidates.
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PKG
Cyclic guanosine monophosphate (cGMP), a second messenger protein
derived from GTP, elicits downstream signaling events through interactions with
intracellular receptor proteins. It is involved in the regulation of smooth muscle
tone, bone growth, platelet aggregation, and electrolyte and fluid
homeostasis[78-80]. Nitric Oxide (NO), produced from nitric oxide synthase, is
the first component involved in the activation of cGMP. NO activates soluble
guanylate cyclases (GC-S), which increase cGMP levels. Cyclic-GMP then
proceeds to bind to and activate a number of downstream substrates [79]. One of
the more prominent receptor substrates of cGMP is the cGMP-dependent protein
kinase (PKG). PKG was first discovered in 1970 in the muscle of lobster tails
[81]. It is a serine/threonine protein kinase whose substrates include receptors,
enzymes and ion channels [82].
The binding of 2 cGMP molecules is required for the complete activation
of one PKG molecule [82]. PKG is a homodimer consisting of two of the same
monomers, each of which contains a regulatory domain and a catalytic domain
on one polypeptide chain [78-80, 82] (Fig. 3). Dimerization, auto-inhibition, and
autophosphorylation all occur at the regulatory domain [79]. The catalytic domain
contains a conserved threonine residue, whose phosphorylation is critical for
relieving auto-inhibition, and essentially for kinase activity [79, 83]. PKG exists in
two homologous forms: PKG I and PKG II. PKG I is localized within the
cytoplasm whereas PKG II is generally associated with the cell membrane [82].
Additionally, there are two isoforms of the type I PKG homologue: PKGIβ and
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A

B

Figure 3. Domain (A) and Crystal (B) Structures of cyclic-GMP-dependent
protein kinase (PKG). (Domain structure adapted from Francis et al.,
Pharmacol. Rev., 2010. Crystal Structure adapted from JJ Kim et al., PLOS One,
2011.)
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PKGIα. These two isoforms are closely related, except in the N-terminal domain
of the PKGIα isoform, which has 16 fewer residues than the PKGIβ isoform [82].
More recently, the NO/cGMP/PKG pathway has been discovered to play
critical roles in cell proliferation and chemoresistance in cancer cells [84, 85].
Studies have shown that cells that express PKGIα and PKGIβ undergo a
biphasic response when exposed to NO. Exposure to low levels of NO results in
activation of PKGIα specifically, leading to cell proliferation and suppression of
apoptosis. This is because the PKGIα isoform has a higher sensitivity to NO than
the PKGIβ isoform. Conversely, a high level of NO leads to activation of both
PKG isoforms, and tends to promote cell apoptosis and suppress cell
proliferation. It is believed that the activation of PKGIβ by high-level NO
contributes to the induction of apoptosis in cancer cells [86].
There have also been studies correlating EGFR activity and PKG
activation. When OV2008 cells, an ovarian cancer cell line, were treated with
increasing EGF ligand concentrations, immunoblot analyses displayed increased
phosphorylation of serine-239 residue of VASP, a PKG-specific protein substrate.
Western blot data from this study also exhibit increased phosphorylation of Src, a
non-receptor tyrosine kinase protein that encodes for the SRC gene. These data
suggest that activation of the EGFR and subsequent PKG activation occurs in a
Src-dependent manner [85].
Recently, activation of PKG by cGMP has become of significant interest
as a novel molecular tool in the induction of apoptosis in cancer [87]. PKG
activation has been shown to induce dose dependent decreases in cell viability,
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as well as time dependent increases in caspases 3 and 9 activity within the MDAMB-468 cell line. The reduction in cell viability due to PKG activation was
remarkably rescued with the addition of a PKG-specific antagonist to the MDAMB-468 cells [87]. Therefore, it is of interest to explore the activation of PKG and
subsequent induction of PKG-mediated apoptosis in regard to EGFR-mediated
apoptosis. Correlation of these two apoptotic pathways within the MDA-MB-468
cell line shows potential in identifying a novel protein with direct implications in
the spatial regulation of the EGFR.
STAT3
In addition to PKG, STAT3 signaling was also shown to be upregulated
with high concentrations of EGF ligand. Signal Transducer and Activator of
Transcription (STAT) proteins were initially discovered as a family of cytoplasmbound transcription factors, which mediate normal cellular responses to growth
factors, cytokines, and ligands [88, 89]. STAT activation is critical for the
mediation of certain biological processes, including cell proliferation, survival,
differentiation, development and inflammation [90]. To date, there are seven
known members of the STAT family expressed in mammalian tissue: STAT1, 2,
3, 4, 5a, 5b, and 6. During activation, STAT proteins become phosphorylated at
their unique critical tyrosine residues (Tyr705 for STAT3). This
phosphorylation/activation process is mediated by growth factor receptor tyrosine
kinases, and cytoplasmic kinases [88, 89]. Phosphorylation occurs at the
cytoplasm, which induces STAT: STAT dimer formation between two monomers
via SH2 domain interactions. From the cytoplasm, the activated STATS
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accumulate in the nucleus, where they initiate and mediate gene transcription by
binding to DNA response elements [88]. This results in either upregulation or
downregulation of the biological processes discussed previously, which are
critical for cellular homeostasis.
Similarly to the EGFR, STAT proteins are implicated in cell growth and
proliferation; however, they are upregulated in cancers and have been known to
induce aberrant signaling in cancer cells. STAT3 has been reported to be
constitutively phosphorylated in human cancer, and has been shown to promote
tumor survival and cancer cell progression [90, 91]. Constitutive STAT3 activity
has been reported in 30-60% of primary mammary malignancies [92]. One study
reports that MDA-MB-468 cells exhibit constitutive activation of STAT3, and that
upon inhibition using a pharmacological inhibitor (5,15-DPP), STAT3:DNA
complexes decrease in a dose dependent manner of inhibitor [93]. These finding
were not observed among the data described within this thesis.
Prior to being implicated in cancer, STAT3-programmed cellular death
was found to be associated with and required for IL-6 induced cell death in
myeloid leukemia [94] and mammary grand involution [95, 96]. After a woman is
finished lactating, the involution process must occur in order to return the
mammary gland to normal size of a “pre-pregnancy” state. This process is reliant
on the post-translational upregulation of STAT3. This leads to downregulation of
serine protease inhibitor 2A (Spi2A), and upregulation of cathepsin B. This
upregulation of cathepsin B leads to the ultimate induction of apoptosis from the
lysosome [97].
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It appears as though STAT3 has been shown to play opposing roles in
mammary tissue. In one instance, it has been shown to potentiate cell growth
and invasion when constitutively active in cancer cells. Contrastingly, it has been
implicated in cell death, being required for mammary gland involution, and even
in leukemia. One of the focuses of this thesis is to define the role and activity of
STAT3 in MDA-MB-468 cells.
In summary, cGMP dependent protein kinase (PKG) plays critical roles in
smooth muscle function and regulation. PKG activity has been implicated in
breast and ovarian cancer. More importantly, PKG activity has been shown to
induce apoptosis in a dose dependent manner of a PKG agonist in MDA-MB-468
cells [98]. Identifying a correlation between PKG-mediated and EGFR-mediated
apoptosis is therefore of interest for the progression of this research project.
STAT3 has also been implicated in cancer. Although this protein is often
associated with cell growth and survival, it is constitutively active in certain breast
cancers, and required for cell death in certain contexts, such as post-lactation
mammary gland involution [97]. It is unknown whether or not PKG and STAT3
have correlations with EGFR-induced apoptosis in MDA-MB-468 cells. It is now
of interest to determine if they are in fact intermediary effectors within this
process.
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MATERIALS AND METHODS
Cell Line
MDA-MB-468 cells were acquired from the American Type Culture Collection
(ATCC) and maintained in Dulbecco’s Modified Eagle Medium (DMEM)
supplemented with 10% Fetal Bovine Serum (FBS), 1% penicillin, 1%
streptomycin, and 2 mM glutamine. The cells were maintained at incubation
conditions of 37 ºC in 5% CO2.

Cell Viability Analyses
1. MTT assay
MTT assays were conducted in order to assess cell viability utilizing the
MDA-MB-468 cells. The MTT assay assesses mitochondrial dehydrogenase
activity based on its ability to cleave the tetrazolium ring of the MTT reagent
(Sigma Aldrich), and subsequently produce formazan. Only mitochondria of
viable cells are capable of such cleavage. Cells were plated at a density of
5,000-10,000 cells with DMEM supplemented with 10% FBS in a 96 well plate.
After a 48 hour incubation period, the cells were washed with PBS and serum
starved for 3 hours in DMEM supplemented with 0.2% BSA. The cells were then
treated with various ligands and reagents in order to induce cell death. After
appropriate incubation periods, the MTT reagent (5 mg/mL in PBS) was added to
each sample within the 96-well plate. The cells were then incubated for 2 hours
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at 37ºC in the absence of CO2. An extraction buffer (20% sodium dodecyl
sulfate, 50% N-dimethylformamide, 50% ddH2O, 80% Acetic Acid, 1M HCl) was
then added to all samples of the 96-well plate in order to extract and solubilize
the formazan crystals. After an additional 30-minute incubation with extraction
buffer at 37ºC in the absence of CO2, the 96-well plate was then analyzed on a
BioTek Synergy HT plate reader and Gen5 BioTek software, at a wavelength of
570 nm. The plate was then read a second time after 24 hours at the same
wavelength.
2. Alamarblue assay
Alamarblue assays were also conducted in order to assess cell viability
within the MDA-MB-468 cells. Resazurin, the active ingredient in the alamarblue
reagent, is reduced to Resorufin in viable cells. Resorufin is highly fluorescent
and viable cells enhance this fluorescence, which can be analyzed and quantified
on a plate reader. Cells were plated at a density of 10,000 cells in DMEM
supplemented with 10% FBS in a 96-well plate. After a 48 hour incubation period,
the cells were washed with PBS and serum starved overnight in serum free
DMEM. The cells were then treated with reagents in order to induce either cell
growth or death. The cells were then incubated in the presence of the various
reagents for 16 hours. The alamarblue reagent was then added as 10% of the
sample volume prior to a 2 hour incubation period. The 96-well plate was then
analyzed on a BioTek Synergy HT plate reader and Gen5 BioTek software, at
wavelengths of 530 nm (excitation) and 590 nm (emission).
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Cell Lysate Preparation and Immunoblot Analyses.
Cell lysates were acquired by washing the cells twice in PBS prior to the
equilibration to 4 ºC and addition of RIPA lysis buffer for cell solubilization (150
mm NaCl, 1% Nonidet P-40, 0.5% deoxycholate, 0.1% SDS, 50 mm Tris (pH
8.0), 10 mm sodium pyrophosphate, 100 mm sodium fluoride, 2 mm
phenylmethyl sulfonyl fluoride). The lysis buffer/cell mixture was then rotated
end-over-end for 10 min at 4 °C, followed by a 10 minute centrifugation period at
15,000 x g, also at 4 °C. The protein concentration of the supernatant from each
sample was then assessed by a BCA assay (Pierce), and samples were
subjected to a 1:3 dilution in SDS sample buffer. Equivalent amounts of protein
(20-40 µg) were separated by either a 7.5%, 10% or 12% SDS-PAGE, prior to
being transferred to nitrocellulose membranes. After being washed in a blocking
reagent to prevent non-specific antibody binding, the membranes were exposed
to various primary antibodies overnight at 4 ºC. The pY99 primary antibody
(Santa Cruz) was used to detect phosphorylated tyrosine residues of the EGFR.
The SC-03 primary antibody (Santa Cruz) was used to detect total
(phosphorylated and non-phosphorylated) EGFR. The α-tubulin (Sigma Aldrich)
as well as GAPDH (Santa Cruz) primary antibodies were used as loading
controls to ensure equivalent amounts of protein were loaded into each lane. The
following antibodies were also employed for studies within this thesis: pY1045
(Cell Signaling), pSTAT3(Tyr705; Cell Signaling), pSTAT1 (Tyr701; Cell
Signaling), STAT3 (Cell Signaling), pMAPK (Cell Signaling), pAKT (Cell
Signaling), pSRC (Cell Signaling), pVASP (Ser239; Cell Signaling), VASP (Cell
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Signaling) and pBAD (Ser112; Cell Signaling). After a 1-hour incubation period
with either anti-mouse (for pY99, α-tubulin and GAPDH) or anti-rabbit (for SC-03,
pSTAT1(Tyr701), pSTAT3(Tyr705) , STAT3, pBAD (Ser112), pVASP(Ser239),
VASP, pMAPK, pAKT, and pSRC) secondary antibodies, the membranes were
washed in TBS-Tween and visualized by ECL reagent using a Fotodyne imaging
system. All western blot data were analyzed and quantified using ImageJ
software.
Statistical Analyses
Treatment groups within each individual MTT and Alamarblue experiments
were quantified to the untreated control to generate percent viabilities for each
experimental condition. These percentages for 3 individual experiments were
then averaged together. Data acquired from both assays are reported as the
means of the percent viabilities ± standard error mean (SEM; n=3) unless
otherwise specified. An unpaired student t-test was then performed for the
determination of significance. Each treatment group was compared to the
untreated, serum free (SF), DMEM control. A p value of less than 0.05 is
designated significant, and is indicated by a single asterisk (*). A p value of less
than 0.01 is designated significant, and is indicated by two asterisks (**). A p
value of less than 0.001 is designated very significant, and is indicated by three
asterisks (***). A p value of less than 0.0001 is designated extremely significant,
and is indicated by four asterisks (****).
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RESULTS

There were two major goals of this project, the first being to determine
whether or not EGFR-induced apoptosis is ligand specific. The second goal was
to identify proteins suspected of having direct implications in the EGFR-induced
apoptotic process in the MDA-MB-468 cell line.
EGF, BTC, and TGFA ligands induce dose dependent decreases in cell
viability in MDA-MB-468 cell line.
The purpose of this study was to investigate the possibility that different
EGFR ligands have differential outcomes on EGFR-mediated viability and or
induction of apoptosis. To assess this possibility, MDA-MB-468 cells were
subjected to an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) cell viability assay upon exposure to EGF, BTC, and TGFA ligands for
16 hours total. All three of these ligands induce a dose dependent decrease in
cell viability. All ligands showed statistical differences at high (16 nM)
concentrations when quantified to the serum free DMEM control treated cells
(Figure 4).
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EGF, BTC, and TGFA all induce a rounded cellular morphology in MDA-MB468 cells.
The purpose of this study was to observe the geometry and morphology of
the MDA-MB-468 cells after exposure to EGF, BTC, and TGFA ligands. When
cells undergo apoptosis, they physically shrink in size, and round in morphology.
We observed the cells at various time points upon exposure to 16 nM
concentrations of each ligand. With increased time, we observed an increase in
the amount of rounded cells versus cells with a viable, cobblestone-like
morphology. At the latest, 24-hour time point, we observed that all cells exposed
to all three ligands were morphologically rounded (Figure 5).
EGF, BTC, and TGFA induce dose dependent increases in EGFR
phosphorylation.
The purpose of this experiment was to expose MDA-MB-468 cells to
increasing concentrations of EGF, BTC, and TGFA ligands in order to compare
and contrast any differences in EGFR phosphorylation patterns by means of
western blot analysis. Cells were exposed to 0, 0.16 nM, 0.5 nM, 1.6 nM, 5 nM,
and 16 nM concentrations of each ligand for 1 hour. Western blot analyses
confirm dose dependent increases in EGFR phosphorylation in response to each
of the three ligands (Figure 6).
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Figure 4.

Dose(Dependent(Decreases(in(MDA<MB<468(Cell(Viability(AAer(Exposure(
to(EGF,(TGFA,(and(BTC.(
110"

100"

*"

Viability(((%(Control)(

90"

80"

**"

70"

**"

60"

50"

40"

30"
0.016"
""""0"

0.16"

1.6"

16"

Log([Ligand]((nM)(

Figure 4. EGF, BTC, and TGFA ligands induce dose dependent decreases
in cell viability in MDA-MB-468 cell line.
Results from an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) cell viability assay. EGF, BTC, and TGFA ligands all induce a dose
dependent decrease in cell viability in the MDA-MB-468 cell line. Data are means
of percent viability ± SEM (n=4). Data were subjected to an unpaired student TTest, each being compared to the untreated, serum free media control. An
asterisk (*) indicates a significance of p<0.05. **, p<0.01.
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Figure 5. EGF, BTC, and TGFA ligands each induce a rounded cellular
morphology in MDA-MB-468 cells.
Cells were exposed to 16 nM concentrations of each ligand and then incubated
for 24 hours total. Photomicrographs (20x) were taken at times 0h, 8h, 16h, and
24h on a Nikon Eclipse Ti Eclipse widefield epifluorescence microscope.
Scale bar = 25 µm
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Figure 6.
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Figure 6. EGF, BTC, and TGFA induce dose dependent increases in EGFR
phosphorylation.
After harvesting the cell lysates, 40 µg of protein from each sample were
resolved on a 7.5% SDS-PAGE. The protein was then transferred to a
nitrocellulose membrane, which was then immunoblotted for either total
phosphotyrosine containing proteins (p-EGFR) (pY99), Total EGFR (Sc-03), or
loading control, α-Tubulin. After incubation with appropriate secondary
antibodies, the nitrocellulose membranes were imaged using a Fotodyne, ECL
system.
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Identifying differences in EGFR-effector signaling between low (1 ng/mL)
and high (100 ng/mL) EGF ligand exposures.
The purpose of this experiment was to expose MDA-MB-468 cells to low
and high EGF concentrations in order to identify any differences in
phosphorylation patterns and effector signaling. As previously mentioned, MDAMB-468 cells undergo cell growth when exposed to low (1 ng/mL) concentrations
of EGF, and apoptosis when exposed to high (≥10 ng/mL) EGF concentrations.
The goal was to subject the cells to both low and high ligand, and then look at
effector signaling in order to identify and differentiate effectors associated with
cell growth, versus those associated with apoptosis. Cells were exposed to each
of the ligand concentrations at various time points for a total of 120 minutes.
Immunoblot analyses allowed for the assessment of pY1045, EGFR, pMAPK,
pAKT, pSRC, pBAD, p-VASP-SER239, and GAPDH (Figure 7).
Mitogen-activated protein kinase 1 (MAPK), Proto-oncogene tyrosineprotein kinase sarcoma (SRC), Protein Kinase B (AKT), and Bcl-associated
Death Protein (BAD) exhibit no significant differences in EGFR signaling at
low versus high ligand concentrations.
These data are a quantification of three separate experiments of the
western blot data, represented in figure 7. Western blot data of all four effectors
were quantified to the loading control for each experiment, GAPDH. No
significant differences between low and high ligand exposures could be
determined in phosphorylated, (p)-MAPK (Figure 8A), p-AKT (Figure 8B), p-SRC
(Figure 8C), or p-BAD (Figure 8D)
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Figure 7.
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Figure 7. Identifying differences in EGFR-effector signaling between low
(1 ng/mL) and high (100 ng/mL) EGF ligand exposures.
After harvesting the cell lysates, 20 µg of protein from each sample were
resolved on a 12% SDS-PAGE. The protein was then transferred to a
nitrocellulose membrane, which was then subjected to immunoblot analyses, to
assess for pY1045, EGFR, pMAPK, pAKT, pSRC, pBAD, p-VASP-SER239, and
GAPDH phosphorylation. After incubation with appropriate secondary antibodies,
the nitrocellulose membranes were imaged using a Fotodyne, ECL system.
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Figure 8.
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Figure 8. MAPK, SRC, AKT, and BAD exhibit no significant differences in
EGFR signaling at low versus high ligand concentrations.
Quantification of three separate experiments of the western blot data represented
in Figure 7. Error bars are expressed as ± SEM. No significant differences in
signaling between low and high EGF ligand exposures could be determined in
phosphorylated, (p)-MAPK (A), p-AKT (B), p-SRC (C), or p-BAD (D).

!

38!

Increases in EGF ligand concentration elicit a dose dependent increase in
p-VASP(SER239) phosphorylation.
The purpose of this experiment was to assess PKG activity, by means of a
p-VASP-SER239 antibody, in order to determine if its activity had any correlation
with EGFR activity. A dose response was conducted, using 0, 1, 3, 10, 30 and
100 ng/mL concentrations of EGF ligand. Data confirm that increases in EGF
ligand induce dosed dependent increases in p-VASP-SER239 phosphorylation
(Figure 9A). Western blot analyses of pY1045 and p-VASP-Ser239 from 3
experiments were both analyzed and quantified to western blots of total EGFR
and total VASP respectively (Figures 9B and 9C). Data from figure 9D are a
quantification of three experiments of the p-VASP-SER239 western blot data,
represented in Figure 7.
PKG agonist, 8-Bromo-cGMP, induces a dose dependent decrease in cell
viability.
The purpose of this experiment was to assess PKG-activation and its
potential role in the induction of apoptosis in MDA-MB-468 cells. Literature has
shown that PKG is able to induce apoptosis within this cell line. It was of interest
to determine if PKG induction of apoptosis had correlation to EGFR-induced
apoptosis. We decided to first assess cell viability by means of an MTT assay in
order to configure an optimal concentration for Annexin V assay, a more accurate
measure of apoptosis. MDA-MB-468 cells were subjected to increasing
concentrations (100 µM, 300 µM, 500 µM, 1 mM, 3 mM, 10 mM) of PKG
activator, 8-Bromo-cGMP (8-Br-cGMP; Sigma) for 48 hours total. Cells treated in
serum free
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Figure 9.
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Figure 9. Increases in EGF ligand concentration elicit a dose dependent
increase in p-VASP(SER239) phosphorylation.
A dose response was conducted, using 0, 1, 3, 10, 30 and 100 ng/mL
concentrations of EGF ligand. Cells were exposed to the 5 different ligand
concentrations for 30 minutes. Twenty µg of protein per sample were then
resolved on a 12% SDS-PAGE (A). Western blot data of p-VASP-SER239 (B)
and pY1045 (B) blot membranes were quantified to total VASP and total EGFR,
respectively. Data from Figure 9D are a quantification of three experiments of the
p-VASP-SER239 western blot data, represented in Figure 7. Error bars are
expressed as ± SEM.

!

40!

DMEM (SF) and DMEM supplemented in 10% FBS (10% FBS) served as
positive controls for viability. Cells treated with 16 nM EGF and 100 nM
Staurosporine (STS) served as negative controls for viability, and positive
controls for apoptosis. Data from this experiment exhibit a clear dose dependent
decrease in MDA-MB-468 cell viability in response to the dose dependent
increases in PKG activation (Figure 10).
The use of PKG agonist, 8-Bromo-cGMP, confirms that PKG does not elicit
EGFR phosphorylation.
The purpose of this experiment was to assess the efficacy of commercially
available PKG inhibitors, as well as the ability of a PKG agonist to activate the
EGFR. The only way of determining if PKG plays a true intermediary role in
EGFR-induced apoptosis is to reduce PKG activity, and then subsequently
assess this effect on apoptosis and viability. The PKG antagonist, (D)-DT-2
(Biolog Life Science Institute; IC50 ~12 nM) was used at 1.25 nM, 12.5 nM, 25
nM, 125 nM, 500 nM, and 1.25 µM concentrations. The PKG agonist, 8-BrcGMP, was used at 10 µM, 30 µM, 100 µM, 300 µM, 1 mM, and 3 mM
concentrations, with an accompanying vehicle control comprised of 33% ddH2O.
The 8-Br-cGMP agonist was employed within this assay as a positive control for
pVASP(Ser239) phosphorylation, whereas cells treated in serum free DMEM
(SF) served as negative controls for EGFR (pY1045) and pVASP(Ser239)
phosphorylation (Figure 11A). The PKG antagonist, Rp-8Br-PET-cGMPs (Biolog
Life Science Institute; IC50 ~25 µM) was used at 1 µM, 3 µM, 10 µM, 30 µM, and
100 µM concentrations, with an accompanying vehicle control comprised of
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0.38% Dimethylformamide (DMF) in DMEM (Figure 11B). The PKG agonist, 8Br-cGMP, was used at 300 µM, 1 mM, 1.3 mM, 2 mM, and 3 mM concentrations,
with an accompanying vehicle control comprised of 33% ddH2O in DMEM. The 8Br-cGMP agonist was employed within this assay as a positive control for
pVASP(Ser239) phosphorylation, whereas cells treated in serum free DMEM
(SF) served as negative controls for EGFR (pY1045) and pVASP(Ser239)
phosphorylation (Figure 11B). Although neither antagonist functioned as
sufficiently as anticipated, it is clear that PKG activation with 8-Bromo-cGMP
does not induce EGFR (pY1045) phosphorylation and subsequent activation.
PSTAT3(Tyr705) is upregulated in both a dose and time dependent manner,
at high EGF ligand concentrations.
The purpose of these experiments was to assess STAT3 signaling when
exposed to low and high EGF concentrations. STAT3 was one of the proteins
assessed in our initial EGFR-effector screening. MDA-MB-468 cells were
subjected to 2-hour time course experiments (Figure 12A. and 12B.), and 30minute dose response experiments (Figure 12C. and 12D.) at low and high
ligand concentrations, as described previously. Data confirm that both STAT1
and STAT3 are upregulated in a time dependent manner, at 100 ng/mL EGF
ligand concentrations. At 1 ng/mL EGF, minimal STAT1 activation and no STAT3
activation was observed. Data from dose response experiments, utilizing 1, 3, 10,
30 and 100 ng/mL EGF, confirm that STAT3 is upregulated in a dose dependent
manner.
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Figure 10.
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Figure 10. Dose dependent increase in PKG activator, 8-Bromo-cGMP,
induces a dose dependent decrease in cell viability.
Results from an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) cell viability assay. Increasing concentrations of a PKG activator induce
a dose dependent decrease in cell viability within the MDA-MB-468 cell line after
48 hours. Data are means of percent viability ± SEM (n=3). Data were subjected
to an unpaired student T-Test, each being compared to the untreated, serum free
(SF) DMEM control. An asterisk (*) indicates a significance of p<0.05. **,
p<0.01. ***, p<0.001. ****, p<0.0001.
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Figure 11.
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Figure 11. The use of PKG agonist, 8-Bromo-cGMP, confirms that PKG
does not elicit EGFR phosphorylation.
A. The PKG antagonist, (D)-DT-2 (IC50 ~12 nM) was used at 1.25 nM, 12.5 nM,
25 nM, 125 nM, 500 nM, and 1.25 µM concentrations. The PKG agonist, 8-BrcGMP, was used at 10 µM, 30 µM, 100 µM, 300 µM, 1 mM, and 3 mM
concentrations, with an accompanying vehicle control (VC) comprised of 33%
ddH2O in DMEM. Forty µg of protein per sample were then resolved on a 12%
SDS-PAGE.
B. The PKG antagonist, Rp-8Br-PET-cGMPs (IC50 = 25 µM) was used at 1 µM, 3
µM, 10 µM, 30 µM, and 100 µM concentrations, with an accompanying vehicle
control comprised of 0.38% Dimethylformamide (DMF). The PKG agonist, 8-BrcGMP, was used at 300 µM, 1 mM, 1.3 mM, 2 mM, and 3 mM concentrations,
with an accompanying vehicle control (VC) comprised of 33% ddH2O in DMEM.
Twenty µg of protein per sample were then resolved on a 12% SDS-PAGE.
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Figure 12.
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Figure 12. pSTAT3(Tyr705) is upregulated in both a dose and time
dependent manner, at high EGF ligand concentrations.
A. MDA-MB-468 cells were subjected to a 2-hour time course experiment,
and were exposed to 1 ng/mL and 100 ng/mL EGF concentrations at various
time points within the 2-hour window frame (0, 15, 30, 60, 90, and 120
minutes). Thirty µg of protein per sample were then resolved on a 12% SDSPAGE.
B. Quantification of three independent time course experiments, represented
in figure 12A. Error bars are expressed as ± SEM.
C. The cells were also subjected to a 30-minute dose response experiment,
and were exposed to ligand concentrations of 1, 3, 10, 30 and 100 ng/mL
EGF.
D. Quantification of three independent dose response experiments,
represented in figure 12C. Error bars are expressed as ± SEM.
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Commercially available STAT3 antagonists exhibit non-specific inhibition
of STAT3 in MDA-MB-468 cells.
The purpose of these experiments was to utilize 2 commercially available
STAT3 inhibitors in order to examine the role of STAT3 in the induction of EGFRmediated apoptosis. MDA-MB-468 cells were exposed to increased
concentrations of 5,15-DPP (Sigma; IC50= 280 nM; Figure 13A.) and STATTIC
(Sigma; IC50= 5.1 µM; Figure 13B.) STAT3 inhibitors. In addition to the dose
dependent decrease in pSTAT3(Tyr705) that each inhibitor induced, both
inhibitors also induced dose dependent inhibition of phosphorylated EGFR
(pY1045).
STATTIC induces a dose dependent decrease in cell viability.
Upon completion of dose response, western blot experiments with the
STATTIC inhibitor, cytotoxicity was observed with each utilized concentration of
inhibitor. Therefore, Alamarblue, cell viability experiments were employed in
order to assess and quantitate the extent of toxicity STATTIC induced within
MDA-MB-468 cells. STATTIC was reconstituted in DMF and cells were treated
with an accompanying vehicle control of 0.31% DMF in DMEM (Figure 14A). It
was also of interest to determine if STATTIC used in combination with 100 ng/mL
EGF ligand induced more apoptosis than STATTIC alone. Alamarblue
experiments confirm that with low (3 µM) STATTIC, 100 ng/mL of EGF appears
to slightly enhance the extent of apoptosis; however, the concentrations of both
EGF and STATTIC alone induced over 50% cell death. Therefore, it was not
possible to fully describe the interaction of the two components in combination
with one another (Figure 14B).
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Figure 13.
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Figure 13. Commercially available STAT3 antagonists exhibit non-specific
inhibition of STAT3 in MDA-MB-468 cells.
A. A dose response experiment was conducted, utilizing 30 nM, 100 nM, 300
nM, and 1 µM concentrations of the 5,15-DPP STAT3 inhibitor. Cells were
also treated with a vehicle control (VC) of 0.34% DMF in DMEM. Upon
harvesting cell lysates, 40 µg of protein per sample were then resolved on
a 12% SDS-PAGE.
B. A second STAT3 inhibitor, STATTIC, was employed at 1 µM, 3 µM, 10
µM, 30 µM, and 100 µM concentrations. The cells were also treated with a
vehicle control (VC) of 0.38% DMF in DMEM. Upon harvesting cell
lysates, 20 µg of protein per sample were then resolved on a 12% SDSPAGE.
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Figure 14.
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Figure 14. STATTIC induces a dose dependent decrease in cell viability.
A. STAT3 inhibitor, STATTIC, was employed in order to examine and
quantify its extent of cytotoxicity. EGF and staurosporine treatments
served as positive controls for apoptosis (n=2 ± SEM). B. STATTIC was
used in combination with 100 ng/mL EGF ligand to determine if the
combination treatment enhanced the induction of apoptosis (n=1).
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siRNA targeting STAT3 are able to significantly reduce STAT3 activity.
The purpose of this experiment was to determine if MDA-MB-468 cells
could be subjected to siRNA knockdown. This determination is critical for
employment of subsequent siRNA, and subsequent analysis of cell viability and
apoptosis. In order to assess this, siRNA targeting STAT3 (Dharmacon; SO2427018G) were employed. Western blot analyses confirm that with the addition
of both STAT3 siRNA, vast reduction in phosphorylated and total STAT3 (78%
reduction) is observed in MDA-MB-468 cells (Figure 15).
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Figure 15.
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Figure 15. siRNA targeting STAT3 are able to significantly reduce STAT3
activity. MDA-MB-468 cells were subjected to 50 nM and 100 nM STAT3 siRNA
for 72 and 96 hours. After allotted time points, cells were harvested, and 20 µg of
protein per sample were then resolved on a 10% SDS-PAGE.
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DISCUSSION
Initial intentions of this study were to understand the molecular
mechanisms that elicit EGFR-mediated apoptosis. In doing so, MDA-MB-468
cells were exposed to various endogenous EGFR ligands and determine their
individual outcomes on cell viability. It was of interest to determine if the EGFR
had ligand specificity within this cell line. Knowing that EGF, BTC, and TGFA
ligands each cause differential endocytic sorting of the receptor [35], it is possible
that these ligands can differentially affect cell viability and apoptosis as well. If
the ligands induce different cellular morphologies and phenotypes, this
information could be useful in determining how the EGFR is spatially regulated
within this cell line. We decided to first assess cell viability in order to determine
optimal time points and concentrations for subsequent apoptosis analyses.
Results from the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) cell viability assay confirm that the MDA-MB-468 cells undergo dose
dependent decreases in cell viability in response to all three ligands (Figure 4).
Cell morphology was assessed upon exposure of the MDA-MB-468 cells
to high (16 nM) concentrations of each ligand. When cells undergo cell death,
they tend to round morphologically. We wanted to physically assess the condition
of the cell by taking bright field images of the cells with increased time. The 24hour images of each of the three-ligand treatment groups showed the same
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rounded cellular morphologies, indicative of cell death (Figure 5). These data
confirm the findings within the MTT analyses.
Lastly, phosphorylation patterns were assessed after exposure to
increasing concentrations of each ligand (0, 0.16 nM, 0.5 nM, 1.6 nM, 5 nM, 16
nM). This assay was conducted in order to assess for any variations in EGFR
phosphorylation patterns. Although BTC ligand had slightly reduced
phosphorylation in comparison to EGF and TGFA ligands, all 3 ligands induced
dose dependent increases in phosphorylation, with similar phosphorylation
patterns (Figure 6).
From these three experiments, we can confidently confirm that different
EGFR ligands do not induce any variation in cell integrity or morphology within
the MDA-MB-468 cell line. All three of these ligands induce cell death
morphology, decreases in cell viability, and have similar EGFR phosphorylation
patterns within our cell line of interest. Therefore, we conclude that EGFRmediated apoptosis from the endosomes is not ligand specific. This
determination means that there is a requirement for a different experimental
approach in order to understand the effector proteins and mechanisms involved
in EGFR-mediated apoptosis and spatial regulation.
The findings within these studies were ultimately anticipated. We suspect
that EGFR-mediated apoptosis is a regulatory mechanism of cancers that hyperexpress this receptor. Low concentrations of EGF ligand results in a lower ratio of
activated receptors, leading to cell growth. Conversely, with high EGF ligand
concentrations, a larger amount of receptors are activated, and cell death occurs
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[44]. We speculate that in MDA-MB-468 cells, high ligand levels elicits high
receptor activation at cell membrane, resulting in the need for an immense level
of ligand:receptor internalization and trafficking at the same time. The endocytic
machinery required for the internalization and trafficking of the receptor is
incapable of efficiently sorting the large number of ligand:receptor complexes,
causing saturation of the endocytic machinery. As a result of this saturation, the
increasingly high levels of activated receptors accumulate at the early endosome.
This causes a disruption in normal cell homeostasis, inevitably resulting in
apoptosis. We ultimately hypothesize that the accumulation at the endosome as
a result of high receptor activation is the underlying culprit of EGFR-mediated
apoptosis in the MDA-MB-468 cell line. Therefore, higher levels of any natural
receptor ligand will still deduce the same extent of receptor activation, and result
in cell death.
It is known that the biological sequence of receptor tyrosine kinases
entails the recruitment of downstream signaling molecules to the phosphorylated
tyrosine residues of the activated receptor dimer [4]. These signaling molecules
are often intermediates in signaling cascades that are ultimately responsible for
cell growth, migration, and in our case apoptosis. Upon EGFR activation, and
internalization within the MDA-MB-468 cell line, we speculate that endosomal
accumulation of the receptor results in the recruitment of resident proteins, and
which are ultimately responsible for initiating the downstream signaling cascade
for the induction of apoptosis. Identifying the kinases/proteins that are recruited
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specifically for the induction of apoptosis is an ideal manner of determining how
the EGFR is spatially regulated in MDA-MB-468 cells, and in cancer.
In addition to the EGFR, activation of cyclic GMP-dependent protein
kinases (PKGs) has been shown to induce dose dependent increases in
apoptosis in MDA-MB-468 cells [98]. Data from our MTT assay, utilizing a potent
activator of PKG (8-Bromo-cGMP) in MDA-MB-468 cells, indicate that increasing
concentrations of the PKG activator result in dose dependent decreases in cell
viability (Figure 10). Our findings from this MTT assay complement the findings
from the literature, and present us with a kinase candidate with a plausible role in
EGFR-mediated apoptosis. Western blot analyses confirm that with the addition
of increasing concentrations of EGF ligand, a dose dependent increase in PKG
activation is observed, by means of a pVASP(Ser239) antibody. Western blot
analyses also confirm that with addition of 3 mM 8-Bromo-cGMP, PKG agonist,
activation of PKG is observed, however, no EGFR phosphorylation in observed.
This is indicative that PKG is downstream of and activated in a dose dependent
manner by the EGFR. Commercially available PKG antagonists, (D)-DT-2 and
Rp-8-Br-PET-cGMPs, did not sufficiently inhibit PKG activity within the MDA-MB468 cell line. The lack of inhibition could be due to the fact that the EGFR is
directly phosphorylating VASP at the serine 239 residue. It is now clear that
siRNA targeting PKG must be employed in order to assess this possibility.
Confirming or refuting PKG as an intermediate in EGFR-mediated apoptosis in
MDA-MB-468 cells is the next step in defining the regulatory mechanisms of the
EGFR in cancer.
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Figure 16.
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Figure 16. Working model for how EGFR-induced apoptosis occurs in a
PKG-mediated manner. The speculation is that PKG is a resident kinase of the
early endosome that is recruited to elicit downstream signaling pathways that
result in the induction of apoptosis.
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It was also of interest to attempt to find other protein candidates that could
potentially be implicated in EGFR-induced apoptosis. Because of this, an EGFReffector screening was conducted. Five proteins, MAPK, AKT, SRC, BAD, and
STAT3 were selected due to their differential roles in various, downstream cell
signaling pathways. Each of these effectors has been implicated with the EGFR
and apoptosis. As previously mentioned, MDA-MB-468 cells undergo cell growth
when exposed to low (1 ng/mL) concentrations of EGF, and apoptosis when
exposed to high ( 10 ng/mL) EGF concentrations. The goal was to subject the
cells to 2-hour time course experiments with low and high ligand, and then look
at signaling within the 5-effector proteins in order to identify and differentiate
effectors associated with cell growth (preferential signaling with low ligand),
versus those associated with apoptosis (preferential signaling with high ligand).
We determined that there was no significant difference in signaling between low
and high EGF concentrations among pAKT, pMAPK, pSRC, and pBAD (Figure
7). Therefore, we chose not to pursue these four proteins for subsequent studies.
The MDA-MB-468 cells were also subjected to dose response
experiments with EGF ligand, and then subsequent western blot analyses of the
dose response experiments. Two protein candidates showed to be dynamically
upregulated in an EGFR dose dependent manner: PKG and STAT3 (Figure 9A
an Figure 12C, respectively). Data within this thesis do not indicate that STAT3 is
constitutively active. Both, dose response and time course data confirm that
STAT3 is inactive at low concentrations, and preferentially activated at high
concentrations of EGF (Figure 12A and Figure 12B). This suggests that the
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EGFR is activating STAT3 at the high EGF concentrations as an intermediate in
the induction of apoptosis. However, it cannot be ruled out that STAT3 is being
activated as a compensatory mechanism, in an attempt to rescue the cell from
EGFR-mediated apoptosis.
In order to assess the role of STAT3 in EGFR-induced apoptosis, two
different STAT3 inhibitors were employed: 5,15-DPP and STATTIC. Although the
5,15-DPP inhibitor was not cytotoxic, it inhibited the EGFR, more than pSTAT3
(Figure 13A). Findings among this thesis also contradict that of the literature,
which reports no reduction in pSTAT3(Tyr 705) phosphorylation with 50 µM
treatment of 5,15-DPP in MDA-MB-468 cells [93]. Similarly to 5,15-DPP,
STATTIC also antagonized the EGFR in a dose dependent manner, completely
blocking EGFR activation at 100 µM. Unlike 5,15-DPP, STATTIC was however
cytotoxic (Figure 14A). An Alamarblue experiment utilizing STATTIC confirmed a
dose dependent decrease in cell viability in response to the STATTIC reagent.
STATTIC was also assessed in combination with a fixed concentration (100
ng/mL) of EGF ligand. If STAT3 is being activated as a compensatory
mechanism, in favor of cell survival, inhibition of STAT3 with the addition of EGF
ligand should potentiate the induction of apoptosis, more than STATTC or EGF
alone. The dose response curve of STATTIC + EGF did seem to potentiate a
decrease in cell viability, but only at low (3 µM) STATTIC concentrations. This is
believed to be due to the fact that at high concentrations, STATTIC inhibits
activation of the EGFR. Potentiation of cell death of the cells exposed to
STATTIC in combination with EGF would not be an expected observation at high
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STATTIC concentrations, because of the minimal EGFR activity occurring. In
order to accurately assess the role of STAT3 in EGFR-induced apoptosis, siRNA
targeting STAT3 must be employed. Through use of readily available siRNA,
targeting STAT3, it can confidently be confirmed that MDA-MB-468 cells are
cable of being subjected to siRNA transfections (Figure 15).
The current model for the role of STAT3 in EGFR-induced apoptosis in
MDA-MB-468 cells exists as 2 scenarios (Figure 17). In the left panel; STAT3 is
an intermediate in EGFR-induced apoptosis. Similarly to the involution process,
STAT3 is upregulated, which causes the post-translational upregulation of
cathepsin B. Cathepsin B upregulation leads to lysosomal induction of apoptosis.
Conversely, in the right panel, STAT3 is upregulated in an attempt to rescue the
cell from EGFR-induced apoptosis. In this portion of the model, STAT3 might be
upregulated, specifically at high concentrations as a “rescue mechanism” to
avoid the cell undergoing apoptosis. This mechanism inevitably fails, however,
which is evidenced by the fact the EGFR-mediated apoptosis occurs in the MDAMB-468 cell line.
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Figure 17. Two models describing the potential roles of STAT3 in EGFRinduced apoptosis in MDA-MB-468 cells. (Adapted from Resemann et al.,
Molecular and Cellular Endocrinology, 2013).
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SUMMARY AND CONCLUSIONS

The research conducted within this thesis attempts to identify any ligand
specificity in EGFR-mediated apoptosis in MDA-MB-468 breast cancer cells. Cell
viability, EGFR-phosphorylation patterns, and cell morphology were all assessed
in the MDA-MB-468 cell line upon exposure to EGF, BTC, and TGFA ligands. All
of the ligands induce dose dependent decreases in viability, as well as dose
dependent increases in EGFR-phosphorylation. Each of the ligands induced
rounded cellular morphologies at high concentrations. These findings are
indicative that there is no ligand specificity in regard to EGFR-mediated
apoptosis within this cell line, and that these cells undergo cell death when
exposed to the 3 ligands. This work helped to unveil the roles of endogenous
EGFR ligands in receptor trafficking and overall cell viability. However, a different
approach had to be employed in order to further understand how the receptor is
spatially regulated within our cell line of interest.
Due to time course and dose response experiments, two protein
candidates have been identified to potentially play an intermediary role in EGFRinduced apoptosis: PKG and STAT3. Ideally, it is of interest to silence each
protein within MDA-MB-468 cells, activate the EGFR, and evaluate their
individual roles in EGFR-mediated apoptosis. Commercially available inhibitors of
both proteins have shown not to properly antagonize their functions.
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Therefore, siRNA knockdown of both PKG and STAT3 will be employed for
subsequent analyses. Sufficient inactivation of PKG and STAT3 will be verified
through immunoblot analyses of total STAT3 and total VASP proteins.

STRENGTHS OF THIS WORK
The major strength of this work lies within use of MDA-MB-468 cell line.
This cell line expressed over one million EGFRs per cell. High receptor
expression will elicit high receptor activation, which is ideal for immunoblot
analysis and ultimate assessment of EGFR phosphorylation. It is also
advantageous that this cell line has a defect in endocytic trafficking, causing the
EGFR to accumulate within the early endosome. This allows for a clear,
manageable determination of EGFR signaling at the subcellular level. Studying
EGFR endocytic trafficking in cells that traffic the receptor efficiently requires the
use of pharmacological reagents to trap the receptor at the desired subcellular
location. Such use of these reagents are not required due to the natural defect
the cells obtain upon EGFR activation and internalization. Overall, this cell line
has a natural, tractable response in regard to EGFR activation, allowing for a
more manageable model to study receptor trafficking and signaling.

LIMITATIONS AND WEAKNESSES
Studies conducted at the cellular level have some unavoidable limitations.
We are assessing the EGFR:ligand interaction solely in our cell line of interest,
and not in vivo. An animal model more accurately recapitulates a human with
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metastatic breast cancer more so than a tissue culture model. An animal or
human model is the only manner of determining if exposure to EGFR ligands has
any effects other than the intended cancer tissue. A tissue culture experimental
model is ideal for preliminary studies, but a major progression within this study
and project would be to assess the findings in a more molecularly complex
organism. Another limitation within this work lies in the use of pharmacological
inhibitors. Data within this thesis confirm that inhibitors can often not antagonize
sufficiently (D-DT-2 and Rp-8-Br-PET-cGMPs), or have non-specific, pleiotropic
effects on other proteins (5,15-DPP and STATTIC). This is a common finding and
hindrance when conducting scientific research. Due to this, we will employ
siRNA to specifically target PKG and STAT3 for sufficient inactivation of each
protein.
FUTURE DIRECTIONS
The ultimate goal is continuously to determine receptor:effector
relationships that have implications in EGFR-induced apoptosis. Therefore,
siRNA knockdown of both PKG and STAT3 will be employed for subsequent
analyses of the role of each protein in EGFR-induced apoptosis within the MDAMB-468 cell line. Further advancement of this project will also rely on determining
if these 2 proteins are spatially regulated within this cell line. This will require
synthesis and employment of EGF ligand, covalently conjugated to polystyrene
beads. This molecular tool will allow us to differentiate signaling occurring at the
cell membrane versus signaling occurring within the endosomes.
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